AU3064800A - The therapeutic use of r-warfarin as anticoagulant - Google Patents

The therapeutic use of r-warfarin as anticoagulant

Info

Publication number
AU3064800A
AU3064800A AU30648/00A AU3064800A AU3064800A AU 3064800 A AU3064800 A AU 3064800A AU 30648/00 A AU30648/00 A AU 30648/00A AU 3064800 A AU3064800 A AU 3064800A AU 3064800 A AU3064800 A AU 3064800A
Authority
AU
Australia
Prior art keywords
warfarin
anticoagulant
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30648/00A
Inventor
Hazel Judith Bardsley
Ann Katherine Daly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901297.3A external-priority patent/GB9901297D0/en
Priority claimed from GBGB9912184.0A external-priority patent/GB9912184D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of AU3064800A publication Critical patent/AU3064800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
AU30648/00A 1999-01-21 2000-01-21 The therapeutic use of r-warfarin as anticoagulant Abandoned AU3064800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9901297 1999-01-21
GBGB9901297.3A GB9901297D0 (en) 1999-01-21 1999-01-21 Diagnostic test and method
GBGB9912184.0A GB9912184D0 (en) 1999-05-25 1999-05-25 Therapeutic use
GB9912184 1999-05-25
PCT/GB2000/000154 WO2000043003A1 (en) 1999-01-21 2000-01-21 The therapeutic use of r-warfarin as anticoagulant

Publications (1)

Publication Number Publication Date
AU3064800A true AU3064800A (en) 2000-08-07

Family

ID=26315012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30648/00A Abandoned AU3064800A (en) 1999-01-21 2000-01-21 The therapeutic use of r-warfarin as anticoagulant

Country Status (2)

Country Link
AU (1) AU3064800A (en)
WO (1) WO2000043003A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003280262A1 (en) * 2002-06-28 2004-01-19 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
EP1673450B1 (en) 2003-10-14 2010-04-28 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US20100034878A1 (en) * 2006-12-19 2010-02-11 Bussey Henry I Combination of vitamin k and vitamin k antagonist such as r-isomer of warfarin, phenprocoumon or r-isomer of phenprocoumon as anticoagulant therapy
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034679A2 (en) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defects in drug metabolism
ES2163036T3 (en) * 1995-07-13 2002-01-16 Du Pont Pharm Co NEW ASYMETRIC SYNTHESIS OF R AND S WARFARINA AND ITS ANALOGS.
DE69826113T2 (en) * 1997-03-11 2005-01-20 Arakis Ltd., Saffron Walden R AND S-ENANTIOMER SEPARATED DOSAGE FORMS

Also Published As

Publication number Publication date
WO2000043003A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
EP1212327B8 (en) Pyrazolopyrimidines as therapeutic agents
AU2955200A (en) Cannula
AU5259100A (en) Medicament
AU4248000A (en) Methods of use of the taci/taci-l interaction
AU2730600A (en) Medical adhesives
AU2919001A (en) Syringe
AU4431000A (en) Novel use
AU7377200A (en) Combination therapy including camptothecin
AU2001260834A1 (en) The treatment of herpes
AU2292301A (en) Human kinases
AU2451500A (en) Therapeutic agents
AU5547000A (en) Novel treatment
AU3978700A (en) Medical use
AU2021601A (en) Composition for the treatment of dandruff
AU4556800A (en) Novel treatment
AU1878201A (en) Composition for the treatment of damaged tissue
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU5973600A (en) Therapeutic agents
AU3714800A (en) Hiv therapy
AU1043601A (en) Medical use
AU4456800A (en) Human hac3
AU1405001A (en) Treatment of diseases
AU5866600A (en) The use of human fgh-8 polypeptides as neurotrophic agents
AU2683500A (en) Compositions for the treatment of pain
AU3133400A (en) Syringe

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase